Two new weapons for defending Hatch-Waxman litigation
Mark Remus of Brinks Gilson & Lione discusses two patent-related challenges for generic pharmaceutical companies and how they might be overcome.
- SPC export waiver: a long road ahead 23-08-2018
- LSIPR 50 2018: Brian Anderson 22-08-2018
- Combination SPCs: shaken and stirred 14-08-2018
- Hatch-Waxman amendment: a Hobson’s choice 08-08-2018
- LSIPR 50 2018: Patrick Leahy 23-07-2018
Latest generics news
Gilead HIV drug not entitled to SPC, says UK court
20-09-2018
The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
